This VIAF Cluster has been deleted. It is no longer part of VIAF.
G. Michael Besser
Besser, Michael G.
VIAF ID: 2176158792840839040007 (Unknown Name Type)
Permalink: http://viaf.org/viaf/2176158792840839040007
Preferred Forms
-
200 _ 1 ‡a Besser ‡b Michael G.
-
100 0 _
‡a
G. Michael Besser
Works
| Title | Sources |
|---|---|
| Atrial natriuretic peptide in physiological doses does not inhibit the ACTH or cortisol response to corticotrophin-releasing hormone-41 in normal human subjects. |
|
| Hormonal and metabolic responses to an enkephalin analogue in normal man |
|
| How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome? |
|
| Hyperprolactinaemia and microadenomas in primary hypothyroidism |
|
| Hypothalamic-pituitary effects of cimetidine |
|
| Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment |
|
| Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy |
|
| Identification of olfactory dysfunction in carriers of X-linked Kallmann's syndrome |
|
| Immunocytochemical study of 18 tumours causing ectopic Cushing's syndrome |
|
| Immunoreactive somatostatin changes during insulin-induced hypoglycaemia and operative stress in man |
|
| In vitro studies on the effects of ranitidine on isolated anterior pituitary and adrenal cells |
|
| Increased beta-endorphin but not met-enkephalin levels in human cerebrospinal fluid after acupuncture for recurrent pain. |
|
| Influence of amphetamines on plasma corticosteroid and growth hormone levels in man. |
|
| Inhibition of CRH-41 release by substance P, but not substance K, from the rat hypothalamus in vitro |
|
| Inhibition of the plasma-aldosterone response to frusemide by bromocriptine |
|
| Inhibition of vasopressin release in man by an opiate peptide |
|
| Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly |
|
| Interleukin-6, a growth promoting cytokine, is present in human pituitary adenomas: an immunocytochemical study |
|
| Interleukins-1 and -6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway |
|
| Intravenous, intramuscular, subcutaneous and intranasal administration of LH-FSH-RH: the duration of effect and occurrence of asynchronous pulsatile release of LH and FSH |
|
| Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome |
|
| Isolated pituitary gonadotrophin deficiency: gonadotrophin secretion after synthetic luteinizing hormone and follicle stimulation hormone-releasing hormone. |
|
| Lack of modulation of the adrenocortical response to ACTH by an opioid peptide |
|
| Late diagnosis of pituitary and parapituitary lesions causing visual failure |
|
| Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity |
|
| Letter: Digital vasospasm with bromocriptine. |
|
| Letter: Dopamine and inhibition of prolactin and growth-hormone secretion |
|
| Letter: Metaclopramide and prolactin |
|
| Linkage analysis of 7 polymorphic markers at chromosome 11p11.2-11q13 in 27 multiple endocrine neoplasia type 1 families |
|
| Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide |
|
| Long-term effects of radiotherapy for acromegaly on circulating prolactin |
|
| Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study |
|
| Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia |
|
| Low dose prednisolone or oestrogen in the treatment of women with late onset or persistent acne vulgaris |
|
| Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors |
|
| Luteinizing hormone secreting adrenal tumour as a cause of precocious puberty |
|
| Lymphocytic hypophysitis: unusual features of a rare disorder. |
|
| Mania in association with hydrocortisone replacement for Addison's disease |
|
| Massive prolactinoma with galactorrhoea in a prepubertal boy. |
|
| Measurement of circulating corticotrophin-releasing factor in man |
|
| Measurement of immunoreactive gamma-MSH in human plasma |
|
| Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up |
|
| Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. |
|
| Menstrual irregularity in women with acromegaly. |
|
| Met-enkephalin circulates in human plasma |
|
| Metastatic parathyroid carcinoma in the MEN2A syndrome |
|
| Metergoline and cyproheptadine suppress prolactin release by a non-5-hydroxytryptaminergic, non-dopaminergic mechanism |
|
| Methodological considerations in the determination of plasma catecholamines by high-performance liquid chromatography with electrochemical detection. |
|
| Metyrapone in long-term management of Cushing's disease |
|
| Mithramycin treatment of malignant hypercalcaemia |
|
| Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies |
|
| Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly |
|
| Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity |
|
| Modulation of the actions of tyrosine by alpha 2-adrenoceptor blockade |
|
| Molecular forms of somatostatin in normal subjects and in patients with pancreatic somatostatinoma |
|
| MRI of pancreatic neuroendocrine tumours |
|
| Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours |
|
| Naloxone inhibits exercise-induced release of PRL and GH in athletes |
|
| Naloxone provokes catecholamine release in phaeochromocytomas and paragangliomas |
|
| Neuroendocrine and cardiovascular responses to high-dose corticosteroid therapy in canine endotoxin shock. |
|
| Neurosurgical Treatment of Nelson’s Syndrome |
|
| No clear evidence for an association between GH replacement and relapse of intracranial germ cell tumours: single centre and KIMS experience |
|
| Normal circulating immunoreactive growth hormone releasing factor (hGRF) concentrations in patients with functional hypothalamic hGRF deficiency |
|
| Normal final height and apparent cure after pituitary irradiation for Cushing's disease in childhood: long-term follow-up of anterior pituitary function |
|
| Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth |
|
| Octreotide |
|
| Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide |
|
| Opiate mediation of amenorrhoea in hyperprolactinaemia and in weight-loss related amenorrhoea |
|
| Opiate modulation of the pituitary-adrenal axis: effects of stress and circadian rhythm |
|
| Opiates control ACTH through a noradrenergic mechanism |
|
| Opioid peptides do not modulate atrial natriuretic peptide or aldosterone release under basal conditions in man. |
|
| Opioids stimulate growth hormone (GH) release in man independently of GH-releasing hormone |
|
